Immuron Overview
- Status
- Public
- Employees
- 4

- Stock Symbol
- IMC

- Share Price
- $0.07
- (As of Tuesday Closing)
Immuron General Information
Description
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Contact Information
- Building 10
- 25-37 Chapman Street
- Blackburn North, Victoria 3131
- Australia
Immuron Stock Performance
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.07 | $0.07 | $0.07 - $0.13 | $16.5M | 228M | 279K | -$0.01 |
Immuron Financials Summary
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 30-Jun-2021 | FY 2020 30-Jun-2020 | FY 2019 30-Jun-2019 |
---|---|---|---|---|
EV | (2,330) | 6,712 | 28,397 | 10,765 |
Revenue | 267 | 109 | 1,687 | 1,707 |
EBITDA | (3,348) | (6,215) | (1,917) | (3,326) |
Net Income | (3,343) | (6,251) | (1,961) | (3,329) |
Total Assets | 18,396 | 20,326 | 4,262 | 5,996 |
Total Debt | 164 | 15 | 42 | 0 |
Immuron Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Immuron‘s full profile, request access.
Request a free trialImmuron Patents
Immuron Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-2986316-A1 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Pending | 19-Apr-2013 | 00000000000 | |
CA-2909636-A1 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Pending | 19-Apr-2013 | 00000000000 | |
US-20160083457-A1 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Granted | 19-Apr-2013 | 00000000000 | |
AU-2014253685-A1 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Granted | 19-Apr-2013 | 00000000000 | |
AU-2014253685-B2 | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | Active | 19-Apr-2013 | C07K16/1282 | 0 |
Immuron Executive Team (7)
Immuron Board Members (5)
Name | Representing | Role | Since |
---|---|---|---|
00000 00000000000 | Immuron | Executive Vice Chairman | 000 0000 |
0000 00000000000 | Immuron | Board Member | 000 0000 |
00000 00000 00.0 | Immuron | Chairman | 000 0000 |
Immuron Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial